Answers are grounded in this paper and cite their sources.
Objective Glucose-dependent insulinotropic polypeptide receptor (GIPR) overexpression has been recently described in a proportion ofgsp−somatotropinomas and suggested to be associated with the paradoxical increase of GH (GH-PI) during an oral glucose load. Design and methods This study was aimed at linking the GIP/GIPR pathway to GH secretion in 25 somatotropinomas-derived primary cultures and correlating molecular with clinical features in acromegalic patients. Given the impairment of the GIP/GIPR axis in acromegaly, an additional aim was to assess the effect of GH/IGF-1 stimulation on GIP expression in the enteroendocrine cell line STC-1. Results Nearly 80% ofGIPR-expressing somatotropinomas, all of them negative forgspmutations, show increased GH secretion upon GIP stimulation, higher sensitivity to Forskolin but not to somatostatin analogs. Besides increased frequency of GH-PI,GIPRoverexpression does not appear to affect acromegalic patients’ clinical features. In STC-1 cells transfected with GIP promoter-driven luciferase vector, IGF-1 but not GH induced dose-dependent increase in luciferase activity. Conclusions We demonstrate thatGIPRmediates the GH-PI in a significant proportion ofgsp−acromegalic patients. In these cases, the stimulatory effect of IGF-1 on GIP promoter support the hypothesis of a functional GH/IGF-1/GIP axis. Further studies based on larger cohorts and the development of a stable transgenic model with inducible GIPR overexpression targeted to pituitary somatotroph lineage will be mandatory to establish the real role of GIPR in the pathogenesis of somatotropinomas.
No takes yet. Share an insight, caveat, or question.
Regazzo et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: